Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

SS (Positive and Negative Symptom Scale) Excited Component (PEC) score, measured at two hours after the first dose. Various assessments of a patient's agitation state were conducted at serial time points using standard agitation scales over the first 4-hour post- dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects were recorded throughout the 24-hour period. The Company expects to release initial results of this trial before the end of September 2008.

A second Phase 3 clinical trial was initiated in July 2008 and is designed to enroll approximately 300 patients diagnosed with bipolar I disorder and acute agitation at 18 U.S. clinical centers. The trial is an in-clinic, multicenter, randomized, double-blind, placebo-controlled study and will test AZ-004 at two dose levels, 5 and 10 mg. Patients may receive up to three doses of study drug in a 24-hour period, depending on their clinical status. Patients eligible for the study include those who are admitted through an emergency department and those who are already in-patients in a hospital setting, as long as they have acute agitation at the time of patient randomization. This study is the first AZ-004 study enrolling bipolar disorder patients. The Company projects that this second Phase 3 clinical trial will take approximately 12 months to complete patient enrollment. The primary endpoint for the study is the change from baseline in the PEC score, measured at two hours after the first dose. Various assessments of a patient's agitation state will be conducted at serial time points using standard agitation scales over the first 4-hour post-dose time period, with follow-up assessments at the end of the 24-hour study period. Side effects will be recorded throughout the 24-hour period. AZ-004 has been licensed to Symphony Allegro, Inc., or Symphony Allegro, and Alexza has the right to repurchase all rights to this product candidate.

-- AZ-001 (Staccato prochlorper
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... -- Immune Pharmaceuticals Inc. ("Immune", the "Company") (NASDAQ: ... its planned bullous pemphigoid (BP) clinical development for bertilimumab, ... is an orphan auto-immune blistering disease of the skin ... Europe . As previously announced, ... II clinical trial in Israel ...
(Date:3/31/2015)... , March 31, 2015 ANI Pharmaceuticals, ... launch of Propafenone Hydrochloride 150mg, 225mg and 300mg oral ... arrhythmias. The overall US market for Propafenone Hydrochloride 150mg, ... per IMS Health. Arthur S. Przybyl ... pleased to announce the launch of our fourth product ...
(Date:3/31/2015)...   Unique Pharmaceuticals , a 503B outsourcing facility, ... company has initiated sterile compounding operations meeting the newly ... company is to meet and exceed industry standards," said ... new regulations is validation of our quality management system ... our industry, investing in its continued success and are ...
Breaking Medicine Technology:Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 2Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 3Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab 4ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 2ANI Pharmaceuticals Announces the Launch of Propafenone Tablets 3Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 2Unique Pharmaceuticals Launches Sterile Operations under New Federal Guidance 3
... Sept. 29 NuVasive, Inc. (Nasdaq: NUVA ), a ... surgical treatments for the spine, announced today that Kevin O,Boyle, ... present at the JMP Securities Healthcare Focus Conference at The ... Tuesday, October 6, 2009, at 12:00 noon ET. , ...
... , , SAN FRANCISCO, Sept. 24 ... groundbreaking PROSPECT ( P roviding R egional O bservations to ... C oronary T ree) clinical trial. PROSPECT is the ... in unexpected heart attacks and the natural progression of coronary artery disease. ...
Cached Medicine Technology:NuVasive to Present at the JMP Securities Healthcare Focus Conference 2NuVasive to Present at the JMP Securities Healthcare Focus Conference 3Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 2Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 3Results from Abbott's PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease 4
(Date:3/31/2015)... (PRWEB) March 31, 2015 A report ... (CASA) at Columbia University states that four out of ... U.S. and enter state juvenile justice systems either test ... under the influence of drugs or alcohol when committing ... Despite this high incidence of substance-related juvenile crime, only ...
(Date:3/31/2015)... A' Design Award and Competition is pleased ... Daniel Dion has been announced as a winner of ... Devices and Research Equipment Design Competition Category. ... behind the award winning Medical Product design Bruker EVOQ ... direction of Dr. Rohan Thakur and the Bruker team ...
(Date:3/31/2015)... PharmMD CEO Robert Yeager ... newly created, senior executive role of Chief Technology Officer ... delivery of high quality, efficient, reliable, and secure applications, ... momentum as a market innovator for Part D Star ... “We were very strategic in our search for the ...
(Date:3/31/2015)... TN (PRWEB) March 31, 2015 Dr. ... welcomes warmer temperatures and sunshine; however, it's important to be ... eye damage. Experts say more than 90 percent ... few precautions and wearing safety glasses. Dr. Shofner shares five ... this season. , 1) Yard Work. While using a lawn ...
(Date:3/31/2015)... Texas (PRWEB) March 31, 2015 ... oxygen therapy equipment and supplies, was recently selected to ... identify online merchants that offer a great shipping experience, ... sites that demonstrate a track record of on-time shipping ... Inc. website, shoppers will see a Google Trusted Store ...
Breaking Medicine News(10 mins):Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2Health News:PharmMD Places Victor Mattingly in C-Suite, Company Focused on Medication Therapy Management and Part D Star Ratings 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 2Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 3Health News:Popular Springtime Activities That Could Cause Irreversible Eye Damage by Renowned Eye Surgeon Dr. Stewart Shofner 4Health News:Sleep Restfully, Inc. now recognized as Google Trusted Store 2
... Addictions ... ... – The YWCA’s Week Without Violence kicks off today, acting as a sober reminder that ... workers throughout the world. Those interested becoming community support workers can enroll in the Addictions ...
... Former pros have lower risk of heart disease, suggesting early ... News) -- A recent report linking professional football to an ... rooms across the nation, but the news for aging athletes ... disease risk factors than other men in the same age ...
... ... Speech Understanding and Discrete Reportable Transcription at the MGMA 2009 Annual Conference, October 11th ... ... ), will be demonstrating the benefits of M*Modal Speech Understanding and Discrete Reportable Transcription ...
... Inc. (Nasdaq: IFLG ), a leading technology provider ... industries, today announced that it has retained SSG Capital ... West Conshohocken, PA to assist InfoLogix in exploring its ... transactions at virtually every level of the capital structure ...
... ... banks are not lending, International Tenant Representative Alliance revisits the most efficient option for ... ... Ronald Pollina, Ph.D., Principal of Pollina Corporate Real Estate and Chairman of the International ...
... The following is the text of a letter to Senator ... Honorable Harry Reid , Majority Leader , United States Senate , ... health care reform debate very carefully. We applaud you and the ... most important and most difficult public policy issue. And, we applaud ...
Cached Medicine News:Health News:YWCA's Week Without Violence Oct. 11-17 a Reminder That Community Support Workers Remain in High Demand 2Health News:Ex-NFL Players Hold Their Own Health-Wise 2Health News:Discrete Reportable Transcription to Populate the EHR/EMR With Physician Dictated Reports 2Health News:Discrete Reportable Transcription to Populate the EHR/EMR With Physician Dictated Reports 3Health News:InfoLogix Announces News Related to its Recent Corporate Development Initiatives 2Health News:Right Now Sale/Leaseback May Be the Only Option to Obtain Cash and a Healthier Balance Sheet 2Health News:Right Now Sale/Leaseback May Be the Only Option to Obtain Cash and a Healthier Balance Sheet 3Health News:Right Now Sale/Leaseback May Be the Only Option to Obtain Cash and a Healthier Balance Sheet 4Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 2Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 3Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 4Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 5Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 6Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 7Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 8Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 9Health News:Concord Coalition Leaders Send Letter to Senator Reid on Healthcare Reform Bill 10
For the quantitative determination of Iron and IBC in serum. Colorimetric method utilizing ferrozine. Endpoint procedure measured at 560 nm. Linearity: 500 ug/dl....
Cholesterol/HDL Standard 50 mg/dl....
For the quantitative determination of High Density Lipoprotein in serum. Available in liquid type. Polyethylene glycol (6000) precipitating reagent. Linearity: 200 mg/dl....
... Intended for the quantitative ... plasma. Two vials, dry ... alphaketoglutarate. Uses NADPH to ... plasma compounds. Reaction: Enzymatic, ...
Medicine Products: